Overview
This is a multi-center open clinical study aimed at evaluating the efficacy and safety of Clifutinib Besylate combined with chemotherapy in newly-treated adult subjects with AML
Description
Main purpose:To evaluate the tolerability and safety of Clifutinib Besylate combined with DA (Cytarabine + Daunorubicin) or AZA (Azacitidine) in newly-treated adult AML subjects; explore reasonable therapeutic doses through climbing tests in different dose groups.
To evaluate the efficacy of Clifutinib Besylate combined with DA or AZA in newly treated adult AML subjects.
Secondary purpose:To observe the pharmacokinetic (PK) characteristics of Clifutinib combined with DA or AZA in newly-treated adult AML subjects and the drug interaction between Clifutinib and AZA at the same time.Observe the correlation of different subtypes and prognostic risk with the efficacy of Clifutinib and the changes of genes before and after treatment.
Eligibility
Inclusion Criteria:
- 1.Cohort 1: 18 years old ≤ age ≤65 years old;Cohort 2: The dose escalation trial
only included AML subjects aged ≥60 years; the extended trial included subjects who
were ≥60 years old or between 18 and 59 years old (including 18 and 59 years old)
and could not tolerate strong chemotherapy.
2.It can be primary AML or AML secondary to MDS, and has not been treated; the extension phase requires the subject to be positive for the FLT3-ITD mutation.
3.The ECOG score according to the requirements of different groups is as follows: Cohort 1: 0~1 points; Cohort 2: Age ≥60 years old: 0~2 points; Age 18~59 years old (including 18 and 59 years old): 0~3 points.
4.Expected survival time ≥ 12 weeks. 5. Subjects must have adequate organ function. 6.subjects voluntarily participated in the study, and signed a written informed consent form by themselves or their guardians.
Exclusion Criteria:
- 1.Diagnosed as APL and manifested as t(15;17)(q22;q12) chromosomal translocation, or
BCR-ABL positive leukemia；Diagnosed as secondary to AML due to previous chemotherapy
or radiotherapy of other tumors; previously received FLT3 inhibitor.
2.AML secondary to myeloproliferative tumor (MPN) or acute lymphoblastic leukemia (ALL).
3.Subjects who have infiltrated the central nervous system in the past or present.
4.Concomitant with other malignant tumors within 5 years before the first medication.
5.Thrombosis or embolism occurred within 12 months before the first medication. 6.Pulmonary function tests indicate that subjects have DLCO ≤50% or FEV1 ≤60%, or have difficulty breathing during rest or require continuous oxygen inhalation.
7.Subjects with uncontrollable, active infections。 8.Clinically obvious gastrointestinal abnormalities, which may affect the intake, transport or absorption of drugs (such as inability to swallow, chronic diarrhea, intestinal obstruction, etc.), or subjects undergoing total gastrectomy。 9.Subjects with a history of psychotropic drug abuse and unable to quit or those with mental disorders。 10.Researchers believe that those who have other severe acute or chronic diseases who are not suitable for participating in clinical trials.